Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
EMD 640744 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Group 1 | EXPERIMENTAL | EMD 640744 30μg and Montanide® ISA 51 VG |
| Group 2 | EXPERIMENTAL | EMD 640744 100μg and Montanide® ISA 51 VG |
| Group 3 | EXPERIMENTAL | EMD 640744 300μg and Montanide® ISA 51 VG |
| Name | Type | Description |
|---|---|---|
| EMD 640744 | BIOLOGICAL | EMD 640744 30μg, weekly in initiation phase and monthly in maintenance phase (in combination with Montanide® ISA 51 VG) |
| Montanide ISA 51 VG | OTHER | Adjuvant. Montanide® ISA 51 VG, weekly in initiation phase and monthly in maintenance phase (in combination with EMD 640744 30ug) |
Inclusion Criteria: * Male and female subjects ≥18 years of age * Signed written informed consent * Histologically or cytologically documented metastatic or locally advanced survivin-expressing solid tumor for which no established therapy exists * Disease must be measurable by RECIST criteria or ev...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
EMD 640744 is an investigational monoclonal antibody being studied for the treatment of advanced solid tumors. It is administered in combination with Montanide ISA 51 VG, an adjuvant, to patients with advanced solid tumors. The drug is currently in Phase 1 clinical development.
EMD 640744 is being developed by Merck KGaA, a German pharmaceutical company. Merck KGaA is publicly traded under the ticker symbol MKGAF. The company is conducting clinical trials to evaluate the safety and efficacy of EMD 640744 in patients with advanced solid tumors.
EMD 640744 is in Phase 1 clinical development. The drug is being studied in a Phase 1 trial for advanced solid tumors. This trial has been completed, and the drug remains investigational, meaning it has not yet been approved by regulatory authorities.
EMD 640744 has been studied in one clinical trial, identified as NCT01012102. This Phase 1 trial, titled 'EMD 640 744 in Montanide ISA 51 VG Administered in Subjects With Advanced Solid Tumors,' enrolled 104 participants aged 18 years and older. The trial has been completed.
EMD 640744 is not FDA approved. It is an investigational drug currently in Phase 1 clinical development for advanced solid tumors. The completed Phase 1 trial evaluated the drug in combination with Montanide ISA 51 VG, but regulatory approval has not been granted.